- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
News Briefs: eMed refiles IPO, acquires Trilix
eMed refiles IPO, acquires TrilixeMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington,
eMed refiles IPO, acquires Trilix
eMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington, MA-based company originally filed for an IPO last August (PNN 9/99) but postponed the offering one month later, citing market volatility with regard to health-related IPOs (PNN 11/99). Apparently sensing a more positive climate on Wall Street these days, eMed refiled its IPO with the Securities and Exchange Commission Feb. 25.
In related news, eMed acquired Trilix Information Systems, a software company founded by several former Cemax-Icon engineers. Trilix, headquartered in Pleasanton, CA, provides integration technology that allows the exchange of information among different healthcare imaging and information systems, both within a hospitals network and via the Internet. The addition of Trilixs technology to eMeds image-management products and services should help facilitate an organizations move toward electronic medical records, providing clinicians with connectivity to diagnostic images, as well as to laboratory, pathology, and other diagnostic reports.
eMed also plans to make Trilixs interface technologies available to other vendors on an OEM basis. Trilix already has OEM relationships with Kodak and Canon, according to company sources. eMed acquired Trilix in a straight stock deal.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
